Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;20(6):234.
doi: 10.3892/etm.2020.9364. Epub 2020 Oct 16.

Research and prospect of peptides for use in obesity treatment (Review)

Affiliations
Review

Research and prospect of peptides for use in obesity treatment (Review)

Yao Gao et al. Exp Ther Med. 2020 Dec.

Abstract

Obesity and its related diseases, such as type 2 diabetes, hypertension and cardiovascular disease, are steadily increasing worldwide. Over the past few decades, numerous studies have focused on the differentiation and function of brown and beige fat, providing evidence for their therapeutic potential in treating obesity. However, no specific novel drug has been developed to treat obesity in this way. Peptides are a class of chemically active substances, which are linked together by amino acids using peptide bonds. They have specific physiological activities, including browning of white fat. As signal molecules regulated by the neuroendocrine system, the role of polypeptides, such as neuropeptide Y, brain-gut peptide and glucagon-like peptide in obesity and its related complications has been revealed. Notably, with the rapid development of peptidomics, peptide drugs have been widely used in the prevention and treatment of metabolic diseases, due to their short half-life, small apparent distribution volume, low toxicity and low side effects. The present review summarizes the progress and the new trend of peptide research, which may provide novel targets for the prevention and treatment of obesity.

Keywords: metabolic diseases; obesity; peptides; peptidomics; treatment.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell. 2001;104:531–543. doi: 10.1016/s0092-8674(01)00240-9. - DOI - PubMed
    1. Haslam DW, James WP. Obesity. Lancet. 2005;366:1197–1209. doi: 10.1016/S0140-6736(05)67483-1. - DOI - PubMed
    1. Executive summary of the clinical guidelines on the identification evaluation and treatment of overweight and obesity in adults. Arch Intern Med. 1998;158:1855–1867. doi: 10.1001/archinte.158.17.1855. - DOI - PubMed
    1. Bray GA, Heisel WE, Afshin A, Jensen MD, Dietz WH, Long M, Kushner RF, Daniels SR, Wadden TA, Tsai AG, et al. The science of obesity management: An endocrine society scientific statement. Endocr Rev. 2018;9:79–132. doi: 10.1210/er.2017-00253. - DOI - PMC - PubMed
    1. Jin J. JAMA patient page. Specific medications for weight loss. JAMA. 2015;314(742) doi: 10.1001/jama.2015.5836. - DOI - PubMed